Etoricoxib PCD Pharma Franchise Company
Cafoli Lifecare offers a comprehensive Etoricoxib PCD pharma franchise built on 11 formulations across tablets and topical ointment, all manufactured at WHO-GMP certified facilities. This gives franchise partners a high-demand pain-management line for orthopaedics and general practice.
What is Etoricoxib?
Etoricoxib is a highly selective COX-2 inhibitor NSAID. By selectively blocking cyclooxygenase-2 it delivers potent anti-inflammatory and analgesic effects while sparing much of the gastric mucosal protection mediated by COX-1, reducing the risk of NSAID-related ulcers. Read its profile on PubChem.
Therapeutic Applications
Etoricoxib is prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout, and acute pain including post-operative dental pain. Its once-daily dosing and the availability of combinations (e.g. with paracetamol) and a topical ointment make it versatile. Prescribers include orthopaedic surgeons, rheumatologists, general physicians and dentists.
Why Etoricoxib is a High-Potential Molecule for Distributors
Etoricoxib has rapidly become a first-line oral NSAID in Indian orthopaedic and pain practice thanks to once-daily convenience and a favourable GI profile. Arthritis and gout are chronic, so patients repeat therapy over long periods, and popular fixed-dose combinations expand the SKU count. With 11 formulations, a distributor can cover every strength and combination demand from a single fast-moving molecule.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Etoricoxib
- PubMed: Etoricoxib literature
Our formulations of Etoricoxib find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: